Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.25)
# 4,383
Out of 5,182 analysts
17
Total ratings
20%
Success rate
-24.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $5.50 | +1,263.64% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.82 | +779.12% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $0.14 | +6,503.08% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.75 | +113.33% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $35.09 | +184.98% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.25 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.57 | +238,753.50% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.67 | +2,142.15% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.83 | +981.21% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.30 | +813.04% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $56.08 | +60.49% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.35 | +13,091.49% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.22 | +2,753,998.36% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $5.50
Upside: +1,263.64%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.82
Upside: +779.12%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $0.14
Upside: +6,503.08%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.75
Upside: +113.33%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $35.09
Upside: +184.98%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.25
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.57
Upside: +238,753.50%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.67
Upside: +2,142.15%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.83
Upside: +981.21%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.30
Upside: +813.04%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $56.08
Upside: +60.49%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.35
Upside: +13,091.49%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.22
Upside: +2,753,998.36%